Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (Nasdaq: LUMO) is a clinical-stage biotechnology company dedicated to developing innovative therapeutics for rare diseases. Headquartered in the United States, Lumos Pharma focuses on creating treatments for conditions such as cancer and rare growth disorders. The company is active in both clinical-stage and preclinical research, emphasizing molecules that enhance the immune system's ability to fight cancer cells.
The company's portfolio includes orally administered treatments, designed to be used alongside other cancer therapies, and a promising Ebola vaccine. Recent achievements highlight the company's progress in its clinical trials, particularly the Phase 2 trials evaluating LUM-201 for moderate Pediatric Growth Hormone Deficiency (PGHD), which have shown significant results in increasing annualized height velocity (AHV). These advancements underscore Lumos Pharma's commitment to addressing unmet medical needs.
Lumos Pharma engages in strategic partnerships with pharmaceutical companies and contracts with manufacturing organizations to ensure the effective production of its treatments. A notable recent development is the appointment of Dr. Pitukcheewanont as Chief Medical Officer. Dr. Duke, with extensive experience in clinical development and medical affairs, has been integral in the advancement of Lumos Pharma's clinical programs.
Financially, Lumos Pharma is in a stable position, with cash on hand expected to support operations through Q3 2024. The company is also gearing up for a Phase 3 trial for LUM-201, poised to be a double-blinded, placebo-controlled clinical trial with a 2:1 randomization in approximately 150 patients. This trial aims to secure the approval of LUM-201 as the first oral therapeutic for moderate PGHD.
Lumos Pharma continues to exhibit its potential through its robust research initiatives, strategic partnerships, and a dedicated team of experts. The company's proactive approach in clinical and preclinical development projects positions it as a significant player in the biotechnology sector, particularly in the realm of rare diseases.
Lumos Pharma (NASDAQ:LUMO) announced the promotion of John McKew, PhD, to President effective August 1, 2021, as part of its succession plan. McKew, who has 30 years of experience in developing therapeutics, previously served as COO and Chief Scientific Officer at Lumos, helping advance the company’s clinical and commercial strategies. He has been instrumental in progressing LUM-201, an oral growth hormone stimulating therapy for pediatric growth hormone deficiency. The company focuses on therapeutics for rare diseases and is currently conducting clinical trials for LUM-201.
Lumos Pharma, Inc. (NASDAQ:LUMO) announced the appointment of Dr. Mark Bach to its Clinical Scientific Advisory Board effective July 15, 2021. Dr. Bach brings over 30 years of clinical research experience, particularly in growth hormone-related disorders. He previously held senior positions at ShouTi Inc. and Ascendis Pharma. The company’s leading candidate, LUM-201, is an innovative oral treatment for Pediatric Growth Hormone Deficiency (PGHD) currently in Phase 2 clinical trials. LUM-201 aims to offer a non-injection alternative to existing therapies, having received Orphan Drug Designation in both the US and EU.
Lumos Pharma, a clinical-stage biopharmaceutical company focused on rare diseases, will announce its Q2 2021 financial results on August 5, 2021, before market open. A conference call is scheduled for 11:00 AM ET to discuss financial results and provide updates on clinical activities. Investors can access the live audio webcast or dial in for participation. Lumos Pharma's lead candidate, LUM-201, is under evaluation for Pediatric Growth Hormone Deficiency and has received Orphan Drug Designation in the US and EU.
Lumos Pharma announced updates on clinical trials for LUM-201, aimed at treating Pediatric Growth Hormone Deficiency (PGHD). The Phase 2 OraGrowtH210 Trial's primary outcome data is now expected in the second half of 2023 due to slower than anticipated enrollment primarily caused by COVID-19 restrictions. The FDA has requested an extension of the trial to 12 months. Additionally, the OraGrowtH212 Trial has been initiated, also extending its treatment period to 12 months. As of June 30, 2021, Lumos holds $107.7 million in cash, sufficient for ongoing operations.
Lumos Pharma has initiated the OraGrowtH212 Trial, a Phase 2 study examining LUM-201 for pediatric growth hormone deficiency (PGHD). This trial aims to document the pharmacokinetics and pharmacodynamics of LUM-201, focusing on its pulsatile release of growth hormone. Conducted at a specialized pediatric hospital in Chile, the trial will assess 24 patients on two dose levels: 1.6 mg/kg/day and 3.2 mg/kg/day over six months. Outcomes include growth hormone pulsatility and safety evaluations. CEO Rick Hawkins expressed optimism about the study supporting future regulatory applications.
AUSTIN, Texas, May 19, 2021 – Lumos Pharma (NASDAQ:LUMO), a biopharmaceutical company focused on rare disease therapeutics, announced participation in the Jefferies Virtual Healthcare Conference on June 3, 2021. The company will conduct a live fireside chat from 3:30 PM to 3:55 PM ET and host one-on-one meetings with investors. The chat can be accessed via the conference link and will be available for replay for 30 days on the company’s website. Lumos Pharma is advancing LUM-201, a growth hormone therapy under Phase 2b trial for Pediatric Growth Hormone Deficiency.
Lumos Pharma, Inc. (NASDAQ:LUMO) announced its participation at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021. The company will present live from 10:45 AM to 11:25 AM ET and will also conduct virtual one-on-one meetings with investors. The presentation can be accessed via the company’s website and will be available for replay for 90 days. Lumos Pharma is focused on therapeutics for rare diseases, with its lead candidate, LUM-201, currently in a Phase 2b trial for Pediatric Growth Hormone Deficiency (PGHD).
Lumos Pharma (NASDAQ:LUMO) reported Q1 2021 results, showing a net loss of $8.6 million, contrasting with a net income of $0.3 million in Q1 2020. Cash and cash equivalents increased to $114.1 million from $98.7 million at the end of 2020, supporting operations through ongoing clinical trials. Updated PK/PD data for LUM-201 demonstrated its potential efficacy in pediatric growth hormone deficiency (PGHD) patients using Predictive Enrichment Markers. The ongoing Phase 2b OraGrowtH210 trial is targeting 40-50 sites, with a mid-2022 data readout anticipated.
Lumos Pharma, Inc. (NASDAQ:LUMO) announced it will report Q1 2021 financial results after market close on May 5, 2021. The company will host a conference call and webcast at 4:30 PM ET to discuss these results and update on clinical activities. The lead therapeutic candidate, LUM-201, is currently in a Phase 2b trial for Pediatric Growth Hormone Deficiency and has Orphan Drug Designation in the US and EU. Investors can access the call via phone or webcast, with a replay available for two weeks.
Lumos Pharma (NASDAQ: LUMO) is holding a Virtual KOL Event today, April 27, 2021, at 10:30 AM ET, featuring new data on its lead asset, LUM-201, for pediatric growth hormone deficiency (PGHD).
KOLs will present findings from the Merck 020 study, highlighting LUM-201's efficacy in increasing pulsatile growth hormone release. Data demonstrates that PEM-positive subjects experienced significant height velocity increases, while one PEM-negative subject showed no benefits.
The event will include corporate updates and a Q&A session.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
What does Lumos Pharma, Inc. specialize in?
What are some of the key products in Lumos Pharma's pipeline?
Where is Lumos Pharma headquartered?
What is the status of Lumos Pharma's clinical trials?
Who is the Chief Medical Officer of Lumos Pharma?
What partnerships does Lumos Pharma engage in?
What is the financial outlook for Lumos Pharma?
What is LUM-201?
Does Lumos Pharma conduct preclinical research?
How does Lumos Pharma's research contribute to cancer treatment?
